key: cord-0964368-ocguwlam
authors: Horby, P.; Lim, W. S.; Emberson, J.; Mafham, M.; Bell, J.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; Prudon, B.; Green, C.; Felton, T.; Chadwick, D.; Rege, K.; Fegan, C.; Chappell, L. C.; Faust, S. N.; Jaki, T.; Jeffery, K.; Montgomery, A.; Rowan, K.; Juszczak, E.; Baillie, J. K.; Haynes, R.; Landray, M. J.; Group, RECOVERY Collaborative
title: Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report
date: 2020-06-22
journal: nan
DOI: 10.1101/2020.06.22.20137273
sha: f37a84afa07094a3a536cfb18adf998cdd642eda
doc_id: 964368
cord_uid: ocguwlam

Background: Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing progression to respiratory failure and death. Methods: The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, adaptive, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19. We report the preliminary results for the comparison of dexamethasone 6 mg given once daily for up to ten days vs. usual care alone. The primary outcome was 28-day mortality. Results: 2104 patients randomly allocated to receive dexamethasone were compared with 4321 patients concurrently allocated to usual care. Overall, 454 (21.6%) patients allocated dexamethasone and 1065 (24.6%) patients allocated usual care died within 28 days (age-adjusted rate ratio [RR] 0.83; 95% confidence interval [CI] 0.74 to 0.92; P<0.001). The proportional and absolute mortality rate reductions varied significantly depending on level of respiratory support at randomization (test for trend p<0.001): Dexamethasone reduced deaths by one-third in patients receiving invasive mechanical ventilation (29.0% vs. 40.7%, RR 0.65 [95% CI 0.51 to 0.82]; p<0.001), by one-fifth in patients receiving oxygen without invasive mechanical ventilation (21.5% vs. 25.0%, RR 0.80 [95% CI 0.70 to 0.92]; p=0.002), but did not reduce mortality in patients not receiving respiratory support at randomization (17.0% vs. 13.2%, RR 1.22 [95% CI 0.93 to 1.61]; p=0.14). Conclusions: In patients hospitalized with COVID-19, dexamethasone reduced 28-day mortality among those receiving invasive mechanical ventilation or oxygen at randomization, but not among patients not receiving respiratory support.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 , emerged in China in late 2019 from a zoonotic source. 1 The majority of COVID-19 infections are either asymptomatic or result in only mild disease. However, a substantial proportion of older infected individuals develop a respiratory illness requiring hospital care, 2 which can progress to critical illness with hypoxemic respiratory failure requiring prolonged ventilatory support. [3] [4] [5] [6] Amongst COVID-19 patients admitted to UK hospitals, the case fatality rate is over 26%, and is over 37% in patients requiring invasive mechanical ventilation. 7 Although remdesivir has been shown to shorten the time to recovery in hospitalized patients, 8 no therapeutic agents have been shown to reduce mortality.

The pathophysiology of severe COVID-19 is dominated by an acute pneumonic process with extensive radiological opacity and, on autopsy, diffuse alveolar damage, inflammatory infiltrates and microvascular thromobosis. 9, 10 The host immune response is thought to play a key role in the pathophysiology of organ failure in other severe viral pneumonias such as highly pathogenic avian influenza, 11 severe acute respiratory syndrome (SARS), 12, 13 and pandemic and seasonal influenza. 14 Inflammatory organ injury may occur in severe COVID-19, with a subset of patients having markedly elevated inflammatory markers such as C-reactive protein, ferritin, and interleukins 1 and 6. 6, 15, 16 Several therapeutic interventions to mitigate inflammatory organ injury have been proposed in viral pneumonia but the value of corticosteroids has been widely debated. 17, 18 In the absence of reliable evidence from large-scale randomized clinical trials, there is great uncertainty about the effectiveness of corticosteroids in COVID-19. Prior to RECOVERY, many COVID-19 treatment guidelines stated that corticosteroids were either 'contraindicated' or 'not recommended' 19 although in China, corticosteroids are recommended for severe cases. 20 Practice has varied widely across the world: in some series, as many as 50% of cases were . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

Baseline data collected using a web-based case report form included demographics, level of respiratory support, major comorbidities, suitability of the study treatment for a particular patient and treatment availability at the study site. Eligible and consenting patients were assigned in a ratio of 2:1 to either usual standard of care or to usual standard of care plus dexamethasone 6 mg once daily (oral or intravenous) for up to 10 days (or until discharge if sooner) or to one of the other suitable and available treatment arms (see Supplementary Appendix) using webbased simple randomization with allocation concealment. For some patients, dexamethasone was either unavailable at the hospital at the time of enrolment or considered by the managing doctor to be either definitely indicated or definitely contraindicated. These patients were excluded from entry in the randomized comparison of dexamethasone vs. usual care and hence are not part of this report. The randomly assigned treatment was prescribed by the treating clinician. Participants and local study staff were not blinded to the allocated treatment.

A single online follow-up form was to be completed when participants were discharged, had died or at 28 days after randomization (whichever occurred earlier). Information was recorded on adherence to allocated study treatment, receipt of other study treatments, duration of admission, receipt of respiratory or renal support, and vital status (including cause of death). In addition, routine health care and registry data were obtained including information on vital status (with date and cause of death); discharge from hospital; intensive care use; and renal replacement therapy.

The primary outcome was all-cause mortality within 28 days of randomization. Secondary outcomes were time to discharge from hospital, and among patients not receiving invasive . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.22.20137273 doi: medRxiv preprint mechanical ventilation at randomization, subsequent receipt of invasive mechanical ventilation (including extra-corporeal membrane oxygenation) or death. Subsidiary clinical outcomes included cause-specific mortality, receipt of renal hemodialysis or hemofiltration, major cardiac arrhythmia (recorded in a subset), and receipt and duration of ventilation.

For the primary outcome of 28-day mortality, the hazard ratio from Cox regression was used to estimate the mortality rate ratio. The few patients (4.8%) who had not been followed for 28 days by the time of the data cut (10 June 2020) were either censored on 8 June 2020 or, if they had already been discharged alive, were right-censored at day 29 (that is, in the absence of any information to the contrary they were assumed to have survived 28 days). Kaplan-Meier survival curves were constructed to display cumulative mortality over the 28-day period. Cox regression was used to analyze the secondary outcome of hospital discharge within 28 days, with patients who died in hospital right-censored on day 29. For the pre-specified composite secondary outcome of invasive mechanical ventilation or death within 28 days (among those not receiving invasive mechanical ventilation at randomization), the precise date of invasive mechanical ventilation was not available and so a log-binomial regression model was used to estimate the risk ratio.

Pre-specified analyses of the primary outcome were performed in five subgroups defined by characteristics at randomization: age, sex, level of respiratory support, days since symptom onset, and predicted 28-day mortality risk. Observed effects within subgroup categories were compared using a chi-square test for trend. Through the play of chance in the unstratified randomization, mean age was 1.1 years higher in those allocated dexamethasone than those allocated usual care (Table 1 ). To account for this imbalance in an important prognostic factor, the estimates of rate ratios and risk ratios (both hereon denoted RR) were adjusted for baseline . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.22.20137273 doi: medRxiv preprint 7 age. This adjustment was not specified in the first version of the statistical analysis plan, but was added once the imbalance in age (a key prognostic factor) became apparent. Results with and without age-adjustment are provided and show that it does not alter the conclusions materially.

Estimates of rate and risk ratios are shown with 95% confidence intervals. All p-values are 2sided and all analyses were done according to the intention-to-treat principle. The full database is held by the study team which collected the data from study sites and performed the analyses at the Nuffield Department of Population Health, University of Oxford.

As stated in the protocol, appropriate sample sizes could not be estimated when the trial was being planned at the start of the COVID-19 pandemic. As the trial progressed, the trial Steering Committee, blinded to the results of the study treatment comparisons, formed the view that, if 28-day mortality was 20% then a comparison of at least 2000 patients allocated to active drug and 4000 to usual care alone would yield at least 90% power at two-sided P=0.01 to detect a clinically relevant absolute difference of 4 percentage points between the two groups (a proportional reduction of one-fifth). Consequently, on 8 June 2020, the Steering Committee closed recruitment to the dexamethasone arm since enrolment exceeded 2000 patients.

Of the 11,320 patients randomized between 19 March and 8 June, 9355 (83%) were eligible to be randomized to dexamethasone (that is dexamethasone was available in the hospital at the time and the patient had no known indication for or contraindication to dexamethasone). Of . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.22.20137273 doi: medRxiv preprint these, 2104 were randomized to dexamethasone and 4321 were randomized to usual care ( Figure S1 ), with the remainder being randomized to one of the other treatment arms. Mean age of study participants in this comparison was 66.1 years (Table 1 ) and 36% patients were female.

A history of diabetes was present in 24% of patients, heart disease in 27%, and chronic lung disease in 21%, with 56% having at least one major comorbidity recorded. In this analysis, 82% of patients had laboratory confirmed SARS-CoV-2 infection, with the result currently awaited for 9%. At randomization, 16% were receiving invasive mechanical ventilation or extracorporeal membrane oxygenation, 60% were receiving oxygen only (with or without non-invasive ventilation), and 24% were receiving neither.

Follow-up information was complete for 6119 (95%) of the randomized patients. Of those allocated to dexamethasone 95% received at least 1 dose (Table S1 ) and the median number of days of treatment was 6 days. 7% of the usual care group received dexamethasone. Use of azithromycin during the follow-up period was similar in both arms (23% vs. 24%) and very few patients received hydroxychloroquine, lopinavir-ritonavir, or interleukin-6 antagonists during follow-up (Table S1 ). Remdesivir only became available for use in the UK under the MHRA Emergency Access to Medicines Scheme on 26 May 2020.

Significantly fewer patients allocated to dexamethasone met the primary outcome of 28 Figure 1A ). In a pre-specified subgroup analysis by level of respiratory support received at randomization, there was a significant trend showing the greatest absolute and proportional benefit among those patients receiving invasive mechanical ventilation at randomization (test for trend p<0.001) (Figure 2 ). Dexamethasone reduced 28-day mortality by 35% in patients receiving invasive mechanical ventilation (rate ratio 0.65 [95% CI . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2020. Figure 1D ). Sensitivity analyses without ageadjustment produced similar findings (Table S2) .

Patients on invasive mechanical ventilation at randomization were on average 10 years younger than those not receiving any respiratory support and had symptoms prior to randomization for 7 days longer (Table 1) . 28-day mortality in the usual care group was highest in those who were receiving invasive mechanical ventilation at randomization (40.7%), intermediate in those patients who received oxygen only (25.0%), and lowest among those who were not receiving respiratory support at randomization (13.2%). Consequently, the greatest absolute reductions in 28-day mortality were seen among those patients on invasive mechanical ventilation.

Patients with longer duration of symptoms (who were more likely to be on invasive mechanical ventilation at randomization) had a greater mortality benefit, such that dexamethasone was associated with a reduction in 28-day mortality among those with symptoms for more than 7 days but not among those with more recent symptom onset (test for trend p<0.001) ( Figure S2 ).

Allocation to dexamethasone was associated with a shorter duration of hospitalization than usual care (median 12 days vs. 13 days) and a greater probability of discharge within 28 days (rate ratio 1.11 [95% CI 1.04 to 1.19]; p=0.002) ( Table 2) with the greatest effect seen among those receiving invasive mechanical ventilation at baseline (test for trend p=0.002) ( Figure S3a ).

Among those not on invasive mechanical ventilation at baseline, the number of patients progressing to the pre-specified composite secondary outcome of invasive mechanical ventilation or death was lower among those allocated to dexamethasone (risk ratio 0.91 [95% CI . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.22.20137273 doi: medRxiv preprint 0.82 to 1.00]; p=0.049) ( Table 2 ) but with significantly greater effects among patients receiving oxygen at randomization (test for trend p=0.008) ( Figure S3b ).

The risk of progression to invasive mechanical ventilation was lower among those allocated dexamethasone vs. usual care (risk ratio 0.76 [95% CI 0.61 to 0.96]; p=0.021) ( Table 2) .

Preliminary analyses indicate no excess risk of any particular cause of death (in particular there was no excess of deaths due to non-COVID infection). More detailed analyses of cause-specific mortality, need for renal dialysis or hemofiltration, and duration of ventilation are in preparation.

These preliminary results show that dexamethasone 6mg per day for up to 10 days reduces 28day mortality in COVID-19 patients receiving invasive mechanical ventilation by one third, and by one fifth in patients receiving oxygen without invasive mechanical ventilation. Similarly, benefit was clearer in patients treated more than 7 days after treatment onset, when inflammatory lung damage is likely to have been more common. However, no benefit was demonstrated in hospitalized COVID-19 patients who were not receiving respiratory support and the results are consistent with possible harm in this group.

RECOVERY is a large, pragmatic, randomized, controlled adaptive platform trial designed to provide rapid and robust assessment of the impact of readily available potential treatments for COVID-19 on 28-day mortality. Around 15% of all UK hospitalized patients with COVID-19 were enrolled in the trial and the control arm fatality rate is consistent with the overall hospitalized case fatality rate in the UK. 7 Only essential data were collected at hospital sites with additional information (including long-term mortality) ascertained through linkage with routine data sources. We did not collect information on physiological, laboratory or virologic parameters. The . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.22.20137273 doi: medRxiv preprint protocol combines the methods of large, simple trials of treatments for acute myocardial infarction in the 1980s with the opportunities provided by digital health care in the 2020s. [23] [24] [25] It has progressed at unprecedented speed, as is essential for studies during epidemics. 26 These preliminary results for dexamethasone were announced on 16 June 2020, just 98 days after the protocol was first drafted, and were adopted into UK practice later the same day. 27 Corticosteroids have been widely used in syndromes closely related to COVID-19, including SARS, MERS, severe influenza, and community acquired pneumonia. However, the evidence to support or discourage the use of corticosteroids in these conditions has been very weak due to the lack of sufficiently powered randomized controlled trials. [28] [29] [30] [31] In addition, the evidence base has suffered from heterogeneity in corticosteroid doses, medical conditions, and disease severity studied. It is likely that the beneficial effect of corticosteroids in severe viral respiratory infections is dependent on using the right dose, at the right time, in the right patient. High doses may be more harmful than helpful, as may corticosteroid treatment given at a time when control of viral replication is paramount and inflammation is minimal. Slower clearance of viral RNA has been observed in patients with SARS, MERS and influenza treated with systemic corticosteroids but the clinical significance of this is unknown. 29, 32, 33 Unlike SARS, where viral replication peaks in the second week of illness, 34 peak viral shedding in COVID-19 appears to be higher early in the illness and declines thereafter. [35] [36] [37] [38] The greater mortality benefit of dexamethasone in patients with COVID-19 who required respiratory support, and among those recruited after the first week of their illness, suggests that at this stage the disease is dominated by immunopathology, with active virus replication playing a secondary role. It is also possible there is an effect via mineralocorticoid receptor binding in the context of SARS-CoV-2 induced dysregulation of the renin-angiotensin system. 39 This would caution against extrapolating the effect of dexamethasone in patients with COVID-19 to patients with other viral respiratory diseases that have a different natural history.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.22.20137273 doi: medRxiv preprint

The RECOVERY trial provides clear evidence that treatment with dexamethasone 6 mg once daily for up to 10 days reduces 28-day mortality in patients with COVID-19 who are receiving respiratory support. Based on these results, 1 death would be prevented by treatment of around 8 patients requiring invasive mechanical ventilation or around 25 patients requiring oxygen (which, in the UK, is recommended when oxygen saturations on room air are 92-94%) 40 without invasive mechanical ventilation. There was no benefit (and the possibility of harm) among patients who did not require oxygen. Prior to the completion of this trial, many COVID-19 treatment guidelines have stated that corticosteroids are either 'contraindicated' or 'not recommended' in COVID-19. 19 These should now be updated, as has already happened within the UK. 27 Dexamethasone provides an effective treatment for the sickest patients with COVID-19 and, given its low cost, well understood safety profile, and widespread availability, is one that can be used worldwide.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2020. Results are count (%), mean ± standard deviation, or median (inter-quartile range). * Includes 6 pregnant women. † SARS-Cov-2 test results are captured on the follow-up form, so are currently unknown for some patients. There was a significant difference (2p=0.008) in mean age of 1.1 years between those randomly allocated dexamethasone and those randomly allocated usual care but no significant differences between these groups in any other baseline characteristic. The 'oxygen only' group includes non-invasive ventilation.

RR=Rate Ratio for the outcomes of 28-day mortality and hospital discharge, and risk ratio for the outcome of receipt of invasive mechanical ventilation or death (and its subcomponents).

Estimates of the RR and its 95% confidence interval are adjusted for age in three categories (<70 years, 70-79 years, and 80 years or older). * Analyses exclude those on invasive mechanical ventilation at randomization. RR=age−adjusted rate ratio. CI=confidence interval. The 'oxygen only' group includes noninvasive ventilation. Note: in the RECOVERY trial press release of 16 June 2020, effects in subgroups of level of respiratory support received were shown with 99% CIs, not 95% CIs as inadvertently stated. The age−adjusted rate ratio and 99% confidence intervals remain . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2020. Results are count (%), mean ± standard deviation, or median (inter-quartile range). * Includes 6 pregnant women. † SARS-Cov-2 test results are captured on the follow-up form, so are currently unknown for some. There was a significant (2p=0.008) difference in mean age between those allocated dexamethasone and those allocated usual care, but no significant differences between these groups in any other baseline characteristic. The 'oxygen only' group includes non-invasive ventilation.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2020. RR=Rate Ratio for the outcomes of 28-day mortality and hospital discharge, and risk ratio for the outcome of receipt of invasive mechanical ventilation or death (and its subcomponents). Estimates of the RR and its 95% confidence interval are adjusted for age in three categories (<70 years , 70-79 years, and 80 years or older). * Analyses exclude those on invasive mechanical ventilation at randomization.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2020. Dexamethasone . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. RR=age−adjusted rate ratio. CI=confidence interval. Subgroup−specific RR estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines through them correspond to the 95% confidence intervals. The 'oxygen only' group includes non−invasive ventilation. Note: in the RECOVERY trial press release of 16 June 2020, effects in subgroups of level of respiratory support received were shown with 99% CIs, not 95% CIs as inadvertently stated. The age−adjusted rate ratio and 99% confidence intervals remain unchanged in this analysis: no oxygen required, RR . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.22.20137273 doi: medRxiv preprint

A Novel Coronavirus from Patients with Pneumonia in China

Estimates of the severity of coronavirus disease 2019: a modelbased analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia

Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Influenza--time to target the host?

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Cytokine release syndrome in severe COVID-19

On the use of corticosteroids for 2019-nCoV pneumonia

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Why do we need some large, simple randomized trials

Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group

The Magic of Randomization versus the Myth of Real-World Evidence

Modernising epidemic science: enabling patient-centred research during epidemics

Dexamethasone in the treatment of COVID-19: Implementation and management of supply for treatment in hospitals

SARS: systematic review of treatment effects

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome

Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis

Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis

Effects of early corticosteroid treatment on plasma SARSassociated Coronavirus RNA concentrations in adult patients

Viral loads and duration of viral shedding in adult patients hospitalized with influenza

Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Viral dynamics in asymptomatic patients with COVID-19

Temporal dynamics in viral shedding and transmissibility of COVID-19

Virological assessment of hospitalized patients with COVID-2019

Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease

Clinical guide for the optimal use of Oxygen therapy during the coronavirus pandemic